HEALTH● LOW1h ago · Nov 3, 2026, 8:00 AM
Chinese drug iza-bren doubles lung cancer survival window in phase 3 trial
South China Morning Post · east asia
An anticancer drug developed by Sichuan Biokin Pharmaceutical took centre stage in a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress in Madrid last week. Researchers said the drug, iza-bren, showed a significant advantage over platinum-based chemotherapy in a phase 3 randomised, double-blind clinical trial conducted at 73 hospitals in China and involving 432 patients with advanced lung cancer. The median progression-free survival (PFS) – the length of...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH51m agoFirst measles death in New York in 30 years, governor points to governmentNOS BuitenlandHEALTH1h agoCoconut oil and cholesterol: why it's "not good business" for the heartClarínHEALTH1h agoChild dies of measles in New York's first in 30 yearsThe Independent WorldHEALTH1h agoNew York Reports First Measles-Related Death In 30 YearsChannels TV